KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Long-Term Deferred Tax (2025)

Rigel Pharmaceuticals has reported Long-Term Deferred Tax over the past 1 years, most recently at $245.9 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $245.9 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $245.9 million (changed N/A YoY), and the annual figure for FY2025 was $245.9 million, changed.
  • Long-Term Deferred Tax for Q4 2025 was $245.9 million at Rigel Pharmaceuticals.
  • Over the last five years, Long-Term Deferred Tax for RIGL hit a ceiling of $245.9 million in Q4 2025 and a floor of $245.9 million in Q4 2025.